口服cfDNA清除纳米系统触发协调性先天-适应性免疫调节,用于炎症性肠病治疗
Oral cfDNA-scavenging nanosystem triggering coordinated innate-adaptive immunomodulation for inflammatory bowel disease therapy
Xinyi Liu, Yunsheng Dou, Mengyao Zhang, Wen Li, Zitong Qiu, Zheyi Li, Huaqing Jing, Yue Zhou, Sona Krizkova, Jining Li, Zbynek Heger, Nan Li
Journal:Acta Pharmaceutica Sinica B
IF:14.6
DOI:10.1016/j.apsb.2026.09.024
PMID:
Published:2026-09-28
research field:免疫学药物递送胃肠病学自身免疫性疾病纳米医学
Abstract
Inflammatory bowel disease (IBD) is an autoimmune disorder characterized by complex changes in the intestinal mucosal immune system. Simultaneous modulation of both innate and adaptive immunity is therefore a promising target for treatment of IBD. Thus, we present an orally administrable system designed to bridge innate and adaptive immune regulation by integrating lysosomal cell-free DNA (cfDNA) scavenging with Zn 2+ -mediated signaling blockade. The presented system is based on zeolitic imidazolate framework-8 (ZIF8) loaded with ε -polylysine ( ε PL) and coated with dextran. Upon reaching the colon, the dextran coating undergoes colon-responsive degradation, subsequently releasing ZIF8- ε PL for uptake by colonic macrophages. In lysosomes, ε PL captures cfDNA, effectively blocking activation of Toll-like receptor 9 (TLR9)/nuclear factor kappa B (NF- κ B) signaling, thereby dampening the innate inflammatory response (triggering a ∼11-fold increase in anti-inflammatory M2 macrophages in vivo ). Simultaneously, Zn 2+ released from ZIF8 inhibits interferon regulatory factor 5 (IRF5) nuclear translocation. This leads to a potent suppression of interleukin-23 (IL-23) production and subsequent inhibition of the IL-23/Th17 axis, restoring the balance between Th17 and regulatory T (Treg) cells (reducing the Th17/Treg ratio by over 50%). Together, ZIF8- ε PL@Dextran disrupts the detrimental crosstalk between innate and adaptive immunity, resulting in effective alleviation of IBD in vivo . Our findings demonstrate that coordinated immunomodulation is a promising next-generation therapeutic modality, paving the way for more effective treatments capable of inducing sustained remission in IBD. The study presents an oral ZIF8- ε PL@Dextran system that simultaneously suppresses innate and adaptive immune pathways, effectively alleviating IBD and restoring immune balance in vivo . Download: Download high-res image (276KB) Download: Download full-size image
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


